A desensitization protocol for the mAb cetuximab

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 1, 2009, Pages 260-262

  Jerath, Maya R ^a,b   Kwan, Mildred ^a,b   Kannarkat, Mily ^b   Mirakhur, Beloo ^c   Carey, Lisa ^a,b   Valgus, John ^b   Platts Mills, Thomas A E ^d   Tarrant, Teresa K ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CARBOPLATIN; CETUXIMAB; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG ANTIBODY; FAMOTIDINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RANITIDINE; STEROID;

ADULT; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; BREAST CANCER; CASE REPORT; CLINICAL PROTOCOL; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEMALE; FLUSHING; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; LETTER; MACULOPAPULAR RASH; METASTASIS; OXYGEN SATURATION; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBOPLATIN; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MIDDLE AGED;

EID: 58149117582     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.09.046     Document Type: Letter

References (9)

1. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
2. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
3. Patel D.D., and Goldberg R.M. Cetuximab-associated infusion reactions: pathology and management. Oncology 20 (2006) 1373-1382
4. Erbitux (cetuximab). [drug product label] (2007), ImClone Systems Incorporated and Bristol-Myers Squibb, New York
5. O'Neil B.H., Allen R., Spigel D.R., Stinchcombe T.E., Moore D.T., Berlin J.D., et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina; association with atopic history. J Clin Oncol 25 (2007) 3644-3648
6. Chung C.H., Mirakhur B., Chan E., Le Q., Berlin J., Morse M., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 358 (2008) 1109-1117
7. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, v3.0 (CTCAE) (2006), National Cancer Institute, Bethesda
8. Nielsen D.L., Pfeiffer P., and Jensen B.V. Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports. Acta Oncol 45 (2006) 1137-1138
9. Cheifetz A., and Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72 (2005) 250-256